FREMONT, Calif., June 9 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that Mark McDade, Chief Executive
Officer, and Andrew Guggenhime, Senior Vice President and Chief Financial
Officer, will participate in several investor conferences in the coming
weeks. The conferences include:
-- Pacific Growth Equities Life Sciences Growth Conference 2006 taking
place in San Francisco, June 12-14. Mark McDade is scheduled to
present at the conference on Monday, June 12 at 5 p.m. EDT, 2 p.m. PDT.
A live webcast of Mr. McDade's presentation will be available through
the PDL website at http://www.pdl.com . Please connect to this website at
least 15 minutes prior to the live webcast to allow time for any
software download that may be needed to hear the webcast. A replay
will be available approximately one hour after completion of the live
webcast, and will remain available for 30 days.
-- Needham & Co. Fifth Annual Biotechnology and Medical Technology
Conference taking place in New York, June 14-15. Andrew Guggenhime is
scheduled to present on Thursday, June 15 at 10:30 a.m. EDT.
-- 16th Annual Wachovia Securities Nantucket Equity Conference taking
place in Nantucket, June 19-22. Andrew Guggenhime is scheduled to
present on Tuesday, June 20 at 8 a.m. EDT.
-- William Blair & Company 26th Annual Growth Stock Conference taking
place in Chicago, June 27-29. Mark McDade is scheduled to present on
Wednesday, June 28 at 3:50 p.m. EDT, 2:50 p.m. CDT or 12:50 p.m. PDT.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. The company currently markets and sells a
portfolio of leading products in the acute-care hospital setting in the
United States and Canada and generates royalties through licensing
agreements with top-tier biotechnology and pharmaceutical companies based
on its pioneering antibody humanization technology. Currently, PDL's
diverse late-stage product pipeline includes six investigational compounds
in Phase 2 or Phase 3 clinical development for hepatorenal syndrome,
autoimmune and inflammatory diseases, cardiovascular disorders and cancer.
Further information on PDL is available at http://www.pdl.com .
PDL BioPharma and the PDL BioPharma logo are considered trademarks of
PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, or ami.knoefler@pdl.com , or Jim
Goff, Investor Relations, +1-510-574-1421, or james.goff@pdl.com
, both of PDL BioPharma, Inc.
|
